title: Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
abstract: Eph receptors constitute the largest family of receptor tyrosine kinases in the human genome. EphA2 is one prominent member that is overexpressed and functionally altered in many invasive cancers, including pancreatic cancer. Dasatinib, which is a multi-targeted kinase inhibitor mainly developed for Bcr-Abl and Src family kinases, has recently been shown to have significant activity against EphA2. As selective small molecule EphA2 inhibitors are not currently available, we investigated the therapeutic potential to target EphA2 by dasatinib in pancreatic cancer cell lines. Using in vitro kinase assays, we found that EphA2 receptor tyrosine kinase was inhibited directly by dasatinib in a dose-dependent manner. Stimulation with ephrinA1 produced rapid increases of EphA2 phosphorylation that were inhibited by dasatinib, although the effects on activation of downstream signalling differed among the pancreatic cancer cell lines. Dasatinib also inhibited ligand-induced binding of EphA2 to the ubiquitin ligase Cbl, and the internalisation and degradation of EphA2, suggesting that these processes are dependent on kinase activity. Treatment with dasatinib decreased EphA2 phosphorylation in BxPC-3 xenografts, suggesting that dasatinib might have activity in pancreatic cancer due to EphA2 inhibition, besides its effects on Src.
authors.affiliation: Division of Applied Molecular Oncology, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada.
authors.forename: Q
authors.initials: Q
authors.lastname: Chang
authors.forename: C
authors.initials: C
authors.lastname: Jorgensen
authors.forename: T
authors.initials: T
authors.lastname: Pawson
authors.forename: D W
authors.initials: DW
authors.lastname: Hedley
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D000069439:Dasatinib; D006801:Humans; D008297:Male; D051379:Mice; D016513:Mice, SCID; D008856:Microscopy, Fluorescence; D010190:Pancreatic Neoplasms / Q000201:enzymology / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D036104:Receptor, EphA2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction; D013844:Thiazoles / Q000494:pharmacology*
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D036104:Receptor, EphA2; D000069439:Dasatinib
references.citation: Oncogene. 2002 Oct 31;21(50):7690-9
references.pmid: 12400011
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32
references.pmid: 16203784
references.citation: J Neurosci. 2004 Jul 14;24(28):6248-57
references.pmid: 15254079
references.citation: Int J Cancer. 1995 Jan 3;60(1):129-36
references.pmid: 7814145
references.citation: Mol Cancer Ther. 2006 Dec;5(12):3014-22
references.pmid: 17148760
references.citation: Curr Biol. 2000 Jan 13;10(1):47-50
references.pmid: 10660304
references.citation: Cancer Res. 2006 Jul 15;66(14):7050-8
references.pmid: 16849550
references.citation: Oncogene. 2000 Nov 20;19(49):5614-9
references.pmid: 11114742
references.citation: Curr Cancer Drug Targets. 2005 May;5(3):149-57
references.pmid: 15892616
references.citation: Am J Pathol. 2006 Mar;168(3):962-72
references.pmid: 16507911
references.citation: Int J Cancer. 2003 Feb 20;103(5):657-63
references.pmid: 12494475
references.citation: Am J Pathol. 2003 Apr;162(4):1037-42
references.pmid: 12651595
references.citation: Clin Cancer Res. 2003 Feb;9(2):613-8
references.pmid: 12576426
references.citation: J Biol Chem. 2003 May 2;278(18):15789-93
references.pmid: 12600984
references.citation: Blood. 2007 Dec 1;110(12):4055-63
references.pmid: 17720881
references.citation: Nat Cell Biol. 2003 Oct;5(10):869-78
references.pmid: 12973358
references.citation: Cancer Res. 2007 Mar 15;67(6):2800-8
references.pmid: 17363602
references.citation: Clin Exp Metastasis. 2006;23(7-8):357-65
references.pmid: 17146615
references.citation: Nature. 1995 Oct 19;377(6550):591-4
references.pmid: 7566171
references.citation: Nat Cell Biol. 2001 May;3(5):527-30
references.pmid: 11331884
references.citation: Genome Biol. 2007;8(11):R255
references.pmid: 18047674
references.citation: Clin Cancer Res. 2001 Nov;7(11):3640-8
references.pmid: 11705887
references.citation: Oncogene. 2003 Jan 30;22(4):548-54
references.pmid: 12555068
references.citation: Cancer Cell. 2005 Aug;8(2):111-8
references.pmid: 16098464
references.citation: Biochem Biophys Res Commun. 2004 Aug 6;320(4):1096-102
references.pmid: 15249202
references.citation: Nat Rev Mol Cell Biol. 2002 Jul;3(7):475-86
references.pmid: 12094214
references.citation: Biochem Soc Trans. 1995 Aug;23(3):446-50
references.pmid: 8566335
references.citation: Nature. 2005 Jun 23;435(7045):1126-30
references.pmid: 15973414
references.citation: Microsc Res Tech. 2002 Oct 1;59(1):58-67
references.pmid: 12242697
references.citation: Neoplasia. 2006 Jan;8(1):18-30
references.pmid: 16533422
references.citation: Cancer Res. 2002 May 15;62(10):2840-7
references.pmid: 12019162
references.citation: J Biol Chem. 1994 Dec 2;269(48):30154-7
references.pmid: 7982920
references.citation: Oncogene. 2000 Dec 7;19(52):6043-52
references.pmid: 11146556
references.citation: Clin Cancer Res. 2007 Jul 15;13(14):4233-44
references.pmid: 17634553
references.citation: J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70
references.pmid: 17077358
references.citation: Nat Cell Biol. 2000 Feb;2(2):62-9
references.pmid: 10655584
references.citation: Nat Biotechnol. 2007 Sep;25(9):1035-44
references.pmid: 17721511
references.citation: Oncogene. 2002 Oct 10;21(46):7011-26
references.pmid: 12370823
references.citation: Cancer Res. 2005 Aug 1;65(15):6910-8
references.pmid: 16061675
references.citation: EMBO J. 1997 Jul 1;16(13):3877-88
references.pmid: 9233798
references.citation: Cancer Res. 2007 Mar 1;67(5):2226-38
references.pmid: 17332353
references.citation: Nat Neurosci. 2004 May;7(5):417-8
references.pmid: 15114347
references.citation: Oncogene. 2005 Nov 24;24(53):7859-68
references.pmid: 16103880
references.citation: Cancer Res. 2001 Mar 1;61(5):2301-6
references.pmid: 11280802
references.citation: Cancer Res. 2004 Feb 1;64(3):910-9
references.pmid: 14871820
references.citation: Nat Rev Cancer. 2004 Jun;4(6):470-80
references.pmid: 15170449
references.citation: Exp Cell Res. 2001 Jul 1;267(1):81-7
references.pmid: 11412040
references.citation: Cell Growth Differ. 1999 Sep;10(9):629-38
references.pmid: 10511313
references.citation: Mol Cancer Res. 2002 Nov;1(1):79-87
references.pmid: 12496371
references.citation: N Engl J Med. 2006 Jun 15;354(24):2531-41
references.pmid: 16775234
references.citation: Nat Genet. 2004 Sep;36(9):979-83
references.pmid: 15300251
references.citation: Clin Exp Metastasis. 2003;20(1):59-68
references.pmid: 12650608
references.citation: J Med Chem. 2004 Dec 30;47(27):6658-61
references.pmid: 15615512
references.citation: Biochem Biophys Res Commun. 2002 Aug 9;296(1):214-20
references.pmid: 12147253